MannKind Corp reports results for the quarter ended December 31 - Earnings Summary

Reuters
02-27
MannKind Corp reports results for the quarter ended December 31 - Earnings Summary
  • MannKind Corp MNKD.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported breakeven earnings per share. The mean expectation of six analysts for the quarter was for earnings of 4 cents per share. Wall Street expected results to range from 3 cents to 5 cents per share.

  • Revenue rose 31.3% to $76.78 million from a year ago; analysts expected $74.99 million.

  • MannKind Corp's reported EPS for the quarter was 3 cents​.

  • The company reported quarterly net income of $7.42 million.

  • MannKind Corp shares had fallen by 12.1% this quarter.

FORECAST CHANGES

  • The mean earnings estimate of analysts had risen by about 20% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for MannKind Corp is $9.50

This summary was machine generated from LSEG data February 26 at 11:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Dec. 31 2024

0.04

0.03

Missed

Sep. 30 2024

0.03

0.02

Missed

Jun. 30 2024

0.01

-0.01

Missed

Mar. 31 2024

0.03

0.04

Beat

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10